101 related articles for article (PubMed ID: 15013920)
21. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
[TBL] [Abstract][Full Text] [Related]
22. Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop.
Smith GL; Ganz PA; Bekelman JE; Chmura SJ; Dignam JJ; Efstathiou JA; Jagsi R; Johnstone PA; Steinberg ML; Williams SB; Yu JB; Zietman AL; Weichselbaum RR; Tina Shih YC
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):450-461. PubMed ID: 28011046
[TBL] [Abstract][Full Text] [Related]
23. Evolution and accomplishments of the Radiation Therapy Oncology Group.
Cox JD
Int J Radiat Oncol Biol Phys; 1995 Oct; 33(3):747-54. PubMed ID: 7558966
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of particle therapy: current evidence and future needs.
Pijls-Johannesma M; Pommier P; Lievens Y
Radiother Oncol; 2008 Nov; 89(2):127-34. PubMed ID: 18707784
[TBL] [Abstract][Full Text] [Related]
25. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C
Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163
[TBL] [Abstract][Full Text] [Related]
26. Prostate tumor alignment and continuous, real-time adaptive radiation therapy using electromagnetic fiducials: clinical and cost-utility analyses.
Quigley MM; Mate TP; Sylvester JE
Urol Oncol; 2009; 27(5):473-82. PubMed ID: 18625565
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
28. Health economic controversy and cost-effectiveness of proton therapy.
Lievens Y; Pijls-Johannesma M
Semin Radiat Oncol; 2013 Apr; 23(2):134-41. PubMed ID: 23473691
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the Radiation Therapy Oncology Group and American Joint Committee on Cancer staging systems among patients with non-small cell lung cancer receiving hyperfractionated radiation therapy. A report of the Radiation Therapy Oncology Group protocol 83-11.
Curran WJ; Cox JD; Azarnia N; Byhardt RW; Shin KH; Emani B; Phillips TL; Selim H; Herskovic A; Mohiuddin M
Cancer; 1991 Aug; 68(3):509-16. PubMed ID: 1648432
[TBL] [Abstract][Full Text] [Related]
30. Taking quality of life into account in health economic analyses.
Weeks J
J Natl Cancer Inst Monogr; 1996; (20):23-7. PubMed ID: 8750463
[TBL] [Abstract][Full Text] [Related]
31. Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis.
Evans WK; Coyle D; Gafni A; Walker H;
Chronic Dis Can; 2003; 24(4):102-7. PubMed ID: 14733759
[TBL] [Abstract][Full Text] [Related]
32. Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.
Lakdawalla DN; Chou JW; Linthicum MT; MacEwan JP; Zhang J; Goldman DP
JAMA Oncol; 2015 May; 1(2):196-202. PubMed ID: 26181023
[TBL] [Abstract][Full Text] [Related]
33. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
Milecki P; Kwias Z; Martenka DJ
Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
[TBL] [Abstract][Full Text] [Related]
34. Economic evaluation alongside cancer trials: methodological and practical aspects.
Bonsel GJ; Rutten FF; Uyl-de Groot CA
Eur J Cancer; 1993; 29A Suppl 7():S10-4. PubMed ID: 8312059
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers?
Bennett CL; Oddone E; Matchar D
Clin Perform Qual Health Care; 1995; 3(3):156-64. PubMed ID: 10151167
[TBL] [Abstract][Full Text] [Related]
36. Menopausal hormone therapy: a systematic review of cost-effectiveness evaluations.
Velentzis LS; Salagame U; Canfell K
BMC Health Serv Res; 2017 May; 17(1):326. PubMed ID: 28476121
[TBL] [Abstract][Full Text] [Related]
37. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.
Stenehjem DD; Bellows BK; Yager KM; Jones J; Kaldate R; Siebert U; Brixner DI
Oncologist; 2016 Feb; 21(2):196-204. PubMed ID: 26614710
[TBL] [Abstract][Full Text] [Related]
38. Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer.
Boyd KA; Jones RJ; Paul J; Birrell F; Briggs AH; Leung HY
BMJ Open; 2015 Oct; 5(10):e007925. PubMed ID: 26482768
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
